SGMT net incomeQ2 2026-$13.95M
SGMT net income was -$13.95M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$10.39M a year earlier. For the full fiscal 2025 it was -$51.04M, compared with -$45.57M in fiscal 2024.
Sagimet Biosciences Inc. (SGMT) financials
For the twelve months ended Jun 30, 2026, Sagimet Biosciences Inc. reported -$47.08M of net income.
- Net income, TTM
- -$47.08M
- EPS, diluted, TTM
- -$1.29
- Cash
- $165.90M
- Market cap
- $804.8M
FY2022FY2025
SGMT revenue and earnings growth
SGMT EPSQ2 2026-$0.26
SGMT diluted EPS was -$0.26 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.58, compared with -$1.45 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | - | - | $2.00M | - |
| Research and development | $39.05M | $38.44M | $19.78M | $24.92M |
| Selling, general and admin | $17.84M | $16.01M | $12.96M | $6.14M |
| Operating income | -$56.89M | -$54.45M | -$30.74M | -$31.05M |
| Income tax | $0 | $0 | - | - |
| Net income | -$51.04M | -$45.57M | -$27.88M | -$30.50M |
| EPS, basic | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
| EPS, diluted | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
| Diluted shares | 32.3M | 31.4M | 10.5M | 184,619 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $35.02M | $75.84M | $75.14M | $158.0K |
| Short-term investments | $78.10M | $75.41M | $19.76M | $32.19M |
| Current assets | $116.40M | $152.77M | $96.65M | $32.79M |
| Total assets | $116.48M | $160.26M | $96.72M | $33.03M |
| Current liabilities | $5.10M | $4.45M | $5.65M | $5.28M |
| Total liabilities | $5.10M | $4.45M | $5.65M | $5.36M |
| Shareholders' equity | $111.38M | $155.81M | $91.06M | -$186.95M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$45.65M | -$42.44M | -$23.77M | -$24.49M |
| Investing cash flow | $4.56M | -$61.68M | $12.58M | -$32.01M |
| Financing cash flow | $275.0K | $104.82M | $86.17M | -$73.0K |
| Stock-based compensation | $6.45M | $5.29M | $4.99M | $1.88M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $0 | $2.00M |
| Research and development | $11.54M | $7.00M | $6.73M | $9.73M | $7.25M | $15.34M | $14.22M | $12.65M | $6.31M | $5.26M | $5.66M | $4.96M |
| Selling, general and admin | $4.28M | $4.72M | $4.03M | $4.60M | $4.68M | $4.52M | $3.98M | $4.25M | $4.28M | $3.51M | $3.81M | $4.49M |
| Operating income | -$15.82M | -$11.71M | -$10.77M | -$14.33M | -$11.93M | -$19.86M | -$18.20M | -$16.90M | -$10.59M | -$8.77M | -$9.47M | -$7.45M |
| Net income | -$13.95M | -$10.65M | -$9.57M | -$12.91M | -$10.39M | -$18.18M | -$16.20M | -$14.62M | -$8.12M | -$6.63M | -$8.15M | -$6.35M |
| EPS, basic | -$0.26 | -$0.33 | -$0.30 | -$0.40 | -$0.32 | -$0.56 | -$0.52 | -$0.45 | -$0.25 | -$0.23 | - | -$0.35 |
| EPS, diluted | -$0.26 | -$0.33 | -$0.30 | -$0.40 | -$0.32 | -$0.56 | -$0.52 | -$0.45 | -$0.25 | -$0.23 | - | -$0.35 |
| Diluted shares | 53.1M | 32.6M | - | 32.5M | 32.2M | 32.2M | - | 32.1M | 31.9M | 29.0M | - | 18.2M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $165.90M | $36.63M | $35.02M | $32.50M | $42.33M | $64.72M | $75.84M | $77.01M | $95.96M | $176.78M | $75.14M | $101.84M |
| Short-term investments | $74.23M | $67.91M | $78.10M | $84.20M | $83.08M | $79.85M | $75.41M | $75.47M | $70.41M | $16.93M | $19.76M | $0 |
| Current assets | $243.99M | $107.72M | $116.40M | $119.48M | $127.20M | $146.07M | $152.77M | $157.19M | $166.75M | $194.49M | $96.65M | $102.82M |
| Total assets | $263.43M | $107.75M | $116.48M | $128.40M | $137.41M | $146.17M | $160.26M | $174.78M | $189.02M | $194.53M | $96.72M | $102.92M |
| Current liabilities | $5.42M | $5.30M | $5.10M | $9.15M | $7.25M | - | $4.45M | - | - | - | $5.65M | $5.05M |
| Total liabilities | $7.28M | - | $5.10M | - | - | $7.18M | $4.45M | $4.09M | $5.73M | $4.51M | $5.65M | $5.05M |
| Shareholders' equity | $256.15M | $102.46M | $111.38M | $119.25M | $130.16M | $138.99M | $155.81M | $170.68M | $183.29M | $190.02M | $91.06M | $97.88M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.10M | -$8.61M | -$11.83M | -$10.18M | -$9.10M | -$14.54M | -$11.02M | -$19.57M | -$5.63M | -$6.21M | -$7.08M | -$3.88M |
| Investing cash flow | -$24.02M | $10.22M | $14.36M | $75.0K | -$13.29M | $3.41M | $9.85M | $624.0K | -$75.16M | $3.00M | -$19.62M | $0 |
| Financing cash flow | - | - | $0 | $274.0K | - | - | $0 | $0 | -$27.0K | $104.85M | $0 | $87.21M |
| Stock-based compensation | $3.69M | $1.84M | $1.69M | $1.69M | $1.60M | $1.47M | $1.53M | $1.55M | $1.45M | $759.0K | $1.31M | $1.85M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | - | - | - | - | - | - | - | - | - | - | - | -372.6% |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | -317.6% |
| Current ratio | 45.02 | 20.34 | 22.82 | 13.06 | 17.55 | - | 34.30 | - | - | - | 17.09 | 20.36 |
Source: XBRL data Sagimet Biosciences Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SGMT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SGMT | - | - | -$47.08M | - | $804.8M |
| MDGL | $1.43B | +92.8% | -$155.46M | -10.9% | $10.06B |
| ALT | $41.0K | +105.0% | -$88.09M | -214861.0% | $375.4M |
| IVA | €7.93M | -46.2% | -€354.14M | -4468.1% | $947.5M |
| VKTX | $0 | - | -$627.20M | - | $3.63B |
SGMT FAQ
5 questionsIs SGMT profitable?
No. Sagimet Biosciences Inc. reported a net loss of $47.08M for the twelve months ended Jun 30, 2026.How much cash and debt does SGMT have?
Sagimet Biosciences Inc. reported $165.90M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is SGMT earnings per share?
Diluted earnings per share were -$1.29 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did SGMT last report financial results?
The latest statements here come from Sagimet Biosciences Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this SGMT financial data come from?
Quantisnow builds these statements from the structured XBRL data Sagimet Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.